Eli Lilly and Co. (NYSE:LLY) is set to report fourth-quarter earnings on Feb. 4 before the opening bell, with Wall Street forecasting a significant revenue beat driven by its blockbuster weight-loss and diabetes drugs.While topline expectations are high, surging research costs could challenge the company's ability to hit ambitious profit targets.Revenue Expectations Vs. GuidanceAnalysts project fourth-quarter revenue of $17.90 billion, as per Benzinga, a figure that exceeds the implied ceiling of management ...